BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, November 24, 2024
See today's BioWorld
Home
» Tracon Licenses D93 Antibody From Micromet
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Tracon Licenses D93 Antibody From Micromet
March 19, 2007
By
Trista Morrison
No Comments
In a deal worth up to $100 million, Micromet Inc. licensed the preclinical anti-angiogenesis monoclonal antibody D93 to privately held Tracon Pharmaceuticals Inc. (BioWorld Today)
BioWorld
